Related Experiment Video
Updated: Jun 23, 2026

Multiplexed Live-Cell Imaging for Drug Responses in Patient-Derived Organoid Models of Cancer
Published on: January 5, 2024
Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment
Kohji Nagano1, Takashi Shinkawa, Hironori Mutoh
1Pharmaceutical Technology Department, Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, Japan. naganokuj@chugai-pharm.co.jp
Abstract:
Here, we report for the first time a comparative phosphoproteomic analysis of distinct tumor cell lines in the presence or absence of the microtubule-interfering agent nocodazole. In total, 1525 phosphorylation sites assigned to 726 phosphoproteins were identified using LC-MS-based technology following phosphopeptide enrichment. Analysis of the amino acid composition surrounding the identified in vivo phosphorylation sites revealed that they could be classified into two motif groups: pSer-Pro and pSer-Asp/Glu. Phosphoproteomic change resulting from nocodazole treatment varied among cell lines in terms of the numbers of total phosphopeptides identified, motif groups, and functional annotation groups; however, the cell lines were equally sensitive to nocodazole. The identified phosphoproteome subset contained major signaling proteins and proteins known to be involved in mitosis, but did not always exhibit the same changes in the tumor cells from nocodazole treatment. In spite of the complex changes observed in the phosphorylation of many of the proteins, possible common features induced by nocodazole were found, including phosphorylation of nucleophosmin (NPM) S254 and coatomer protein complex, subunit alpha (COPA) S173, suggesting that the events are not cell-type specific but events generally occurring in mitosis or induced by a microtubule-interfering agent. Further, temporal analysis of phosphoproteome change revealed that phosphorylation of NPM S254 and COPA S173 was observed from the early (6 h) and late (24 h) time point after nocodazole treatment, respectively, suggesting that NPM S254 may be involved in the induction of M-phase arrest by nocodazole, whereas COPA S173 may be caused as a result of M-phase arrest.
Insights
This study compared phosphoproteomic changes in tumor cells treated with nocodazole, a microtubule-interfering agent. Common phosphorylation events, like those in nucleophosmin (NPM) and coatomer protein (COPA), were identified, suggesting general mitotic responses.
Area of Science:
- Proteomics
- Cell Biology
- Molecular Oncology
Background:
- Microtubule-interfering agents are crucial in cancer therapy.
- Understanding cellular responses to these agents at the phosphoproteome level is vital.
Purpose of the Study:
- To conduct a comparative phosphoproteomic analysis of distinct tumor cell lines treated with nocodazole.
- To identify common and distinct phosphorylation changes induced by nocodazole treatment.
Main Methods:
- Liquid chromatography-mass spectrometry (LC-MS)-based phosphoproteomics.
- Phosphopeptide enrichment and subsequent quantitative analysis.
- Bioinformatic analysis of phosphorylation sites, motifs, and functional annotations.
Main Results:
- Identified 1525 phosphorylation sites on 726 phosphoproteins across different cell lines.
- Observed cell-line-specific variations in phosphoproteomic changes but equal sensitivity to nocodazole.
- Identified common phosphorylation events, including nucleophosmin (NPM) S254 and coatomer protein complex, subunit alpha (COPA) S173, suggesting general mitotic responses.
Conclusions:
- Nocodazole treatment induces complex, yet partially conserved, phosphoproteomic changes in tumor cells.
- NPM S254 phosphorylation may contribute to M-phase arrest, while COPA S173 phosphorylation might be a consequence of it.
- These findings provide insights into the molecular mechanisms of microtubule-interfering agents.
More Related Videos
12:41Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018